业绩经营情况 经济观察网 微泰医疗-B的核心产品LinX持续葡萄糖监测系统（CGM）于2025年12月23日获得巴西上市 批准，适用于成人和儿童糖尿病患者。巴西是拉丁美洲核心市场，患病人数全球第六，糖尿病支出全球 第三，此次获批将推动公司2026年海外业务加速扩张。公司产品已进入欧洲多国医保体系，并销往全球 118个国家和地区，国际化布局有望持续深化。 以上内容基于公开资料整理，不构成投资建议。 产品研发进展 公司研发管线包括第二代Equil贴敷式胰岛素泵、混合闭环胰岛素输注系统及人工胰腺系统，其中儿童 适应症（3-17岁）已于2025年9月获中国药监局批准，将成为2026年增量来源。同时，公司通过内部AI 团队与科研院所合作，探索AI大模型在CGM领域的应用，推动"设备+算法+云平台"模式升级。 2025年"双十一"期间，公司CGM产品全网GMV增长218%，二代动态血糖仪出货量同比增长622.8%，新 用户数增长300%，线上渠道放量显著。中信建投证券指出，2026年CGM产品在国内将通过"电商+院 内"双渠道延续高增长，海外市场因基数小、医保准入扩大，收入增速预计保持高位。利润端，2025年 H1归母净 ...

Core Viewpoint - The article highlights the innovative advancements of Weitai Medical in the diabetes management sector, particularly focusing on the upcoming launch of its hybrid closed-loop insulin infusion system, which is expected to be the first domestically produced artificial pancreas system in China [6][7][10]. Group 1: Product Overview - Weitai Medical's hybrid closed-loop insulin infusion system integrates a dynamic blood glucose monitor, an insulin pump, and an AI algorithm for automatic insulin delivery adjustment, aiming to enhance blood sugar control and patient quality of life [7][8]. - The system is designed to provide seamless monitoring and decision-making, significantly reducing the need for manual intervention, especially during nighttime [8]. - The company has developed a new generation of dynamic blood glucose monitors, AiDEX X, which is compact, easy to use, and capable of continuous monitoring for 15 days [9]. Group 2: Market Position and Strategy - With over 140 million adult diabetes patients in China, the market for diabetes management products is substantial, and Weitai Medical aims to break the dominance of foreign competitors by offering more affordable solutions [11][12]. - The company has achieved significant growth in the dynamic blood glucose monitor sector, with estimates suggesting that domestic brands may soon surpass international giants in market share [12]. - Weitai Medical plans to expand its market penetration for dynamic glucose monitors and insulin pumps while pushing for innovation in diabetes management towards automation and personalization [13]. Group 3: Technological Innovation - Weitai Medical has established a comprehensive product ecosystem in diabetes management, including monitoring devices, treatment devices, and software platforms, which positions it uniquely in the market [10]. - The company has invested heavily in R&D, collaborating with top universities and establishing research centers to drive innovation in diabetes care [12]. - The upcoming artificial pancreas system represents a culmination of over a decade of technological advancements and clinical practice integration by Weitai Medical [10].